The Influence of Sex, Ethnicity, and CYP2B6 Genotype on Bupropion Metabolism as an Index of Hepatic CYP2B6 Activity in Humans by Ilic, K. et al.
1521-009X/41/3/575–581$25.00 http://dx.doi.org/10.1124/dmd.112.048108
DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 41:575–581, March 2013
U.S. Government work not protected by U.S. copyright
The Influence of Sex, Ethnicity, and CYP2B6 Genotype on
Bupropion Metabolism as an Index of Hepatic CYP2B6
Activity in Humans
Katarina Ilic,1 Roy L. Hawke, Ranjit K. Thirumaran, Erin G. Schuetz, J. Heyward Hull, Angela D.
M. Kashuba, Paul W. Stewart, Celeste M. Lindley, and Mei-Ling Chen
Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy (K.I., R.L.H., J.H.H.,
A.D.M.K., C.M.L), Biostatistics Department, School of Public Health (P.W.S.), University of North Carolina, Chapel Hill,
North Carolina; University of Belgrade, School of Pharmacy, Belgrade, Serbia (K.I.); Department of Pharmaceutical
Sciences, St. Jude Children’s Research Hospital, Memphis, Tennessee (R.K.T., E.G.S.); and Office of Pharmaceutical
Science, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland (M.L.C.)
Received July 31, 2012; accepted December 13, 2012
ABSTRACT
The effects of sex, ethnicity, and genetic polymorphism on hepatic
CYP2B6 (cytochrome P450 2B6) expression and activity were
previously demonstrated in vitro. Race/ethnic differences in CYP2B6
genotype and phenotype were observed only in women. To identify
important covariates associated with interindividual variation in
CYP2B6 activity in vivo, we evaluated these effects in healthy
volunteers using bupropion (Wellbutrin SR GlaxoSmithKline, Re-
search Triangle Park, NC) as a CYP2B6 probe substrate. A fixed 150-
mg oral sustained-release dose of bupropion was administered to
100 healthy volunteers comprising four sex/ethnicity cohorts (n = 25
each): Caucasian men and Caucasian, African American, and
Hispanic women. Blood samples were obtained at 0 and 6 hours
postdose for the measurement of serum bupropion (BU) and
hydroxybupropion (HB) concentrations. Whole blood was obtained
at baseline for CYP2B6 genotyping. To characterize the relationship
between CYP2B6 activity and ethnicity, sex, and genotype when
accounting for serum BU concentrations (dose-adjusted log10-
transformed), analysis of covariance model was fitted in which the
dependent variable was CYP2B6 activity represented as the log10-
transformed, metabolic ratio of HB to BU concentrations. Several
CYP2B6 polymorphisms were associated with CYP2B6 activity.
Evidence of dependence of CYP2B6 activity on ethnicity or genotype-
by-ethnicity interactions was not detected in women. These results
suggest that CYP2B6 genotype is the most important patient variable
for predicting the level of CYP2B6 activity in women, when measured
by the metabolism of bupropion. The bupropion metabolic ratio ap-
pears to detect known differences in CYP2B6 activity associated with
genetic polymorphism, across different ethnic groups. Prospective
studies will be needed to validate the use of bupropion as a probe
substrate for clinical use.
Introduction
Cytochrome P450 2B6 (CYP2B6) represents approximately 5% of
the total liver microsomal CYP content (Gervot et al., 1999; Stresser
and Kupfer 1999). Its expression and enzyme activity has been shown
to vary approximately 100-fold in human liver (Faucette et al., 2000).
CYP2B6 is also expressed in extrahepatic tissues such as brain, kidney,
intestine (Gervot et al., 1999), uterine endometrium (Hukkanen et al.,
1998), skin (Janmohamed et al., 2001), lung (Ding and Kaminsky,
2003), and heart (Thum and Borlak, 2000). CYP2B6 can partially or
completely metabolize approximately 70 substrates (Ekins et al., 1998;
Ekins and Wrighton, 1999). It has been shown that CYP2B6 contributes
to the metabolism of the anticancer pro-drugs cyclophosphamide
(Chang et al., 1993) and ifosphamide (Roy et al., 1999) and to the
nonnucleosidic reverse transcriptase inhibitors such as efavirenz (Ward
et al., 2003) and nevirapine (Erikson et al., 1999).
CYP2B6 is one of the most polymorphic cytochrome P450 (P450)
genes in humans and currently has 30 defined alleles with over 100
described polymorphisms (http://www.imm.ki.se/CYPalleles/cyp2b6.
htm). CYP2B6 gene polymorphism includes copy number variants,
missense mutations, insertions and deletions, and mutations affecting
gene expression and activity. The polymorphic nature of the cytochrome
P450 (CYP450) genes affects individual drug response and adverse
reactions to a great extent (Ingelman-Sundberg et al., 2007). Studies of
This work was supported by the Office of Women’s Health, U.S. Food and Drug
Administration [Grant FRP#: FDA-SOL-05-00050]. K. I. was a drug research and
development fellow (2006-2008) supported by GlaxoSmithKline.
1Current affiliation: School of Pharmacy, University of Belgrade, Belgrade,
Serbia.
Parts of the data in this article were presented at the American Society for
Clinical Pharmacology and Therapeutics Annual Meeting; 2–5 April 2008; Orlando,
FL. [published in abstract form: Ilic K, Hogeland G, Rezk N, White N, Lamba J, Lee
C, Kasuba ADM, Schuetz EG, Lindley CM, Chen ML, and Hawke RL (2008) The
influence of sex, race/ethnicity and CYP2B6 genotype on bupropion metabolism.
Clin Pharm Ther 83:81].
dx.doi.org/10.1124/dmd.112.048108.
ABBREVIATIONS: AAW, African-American women; ANCOVA, analysis of covariance; AUC, area under the curve; BMI, body mass index; BU,
bupropion; CAW, Caucasian-American women; CAM, Caucasian-American men; CYP2B6, cytochrome P450 2B6; HAW, Hispanic-American
women; HB, hydroxybupropion; MR, metabolic ratio; P450, cytochrome P450; PCR, polymerase chain reaction; SNP, single nucleotide
polymorphisms.
575
human liver tissues have shown that women tend to express higher levels
of CYP2B6 in liver than men (Lamba et al., 2003). Race/ethnic
differences in CYP2B6 genotype and phenotype were observed in
women, but not in men. The CYP2B6 activity was 3.6- and 5.0-fold
higher, respectively, in Hispanic women than in Caucasian (P , 0.022)
and African-American (P , 0.038) women. The level of CYP2B6
expression has also been linked to genetic polymorphism. Single
nucleotide polymorphisms (SNPs) in intron-3 break point 15582C.T
(which is frequently in combination with the exon-4 516G.T and
influences CYP2B6 alternative splicing) and the exon-9 1459C.T SNP
were reported to result in low CYP2B6 activity in women but not men
(Lamba et al., 2003).
Several probe substrates have become extremely useful in vitro and
in vivo for evaluating cytochrome P450 activity (Tucker et al., 1998;
Streetman et al., 2000). However, only two CYP2B6 substrates have
emerged as potential probe substrate for quantifying the level of
CYP2B6 activity in humans. In vitro investigations using human liver
microsomes and recombinant P450s suggest that CYP2B6 is the
primary P450 enzyme catalyzing the metabolism of bupropion
(Faucette et al., 2000; Hesse et al., 2000) and efavirenz (Ward et al.,
2003).
Stereoselective bupropion hydroxylation has been used as in vivo
phenotypic probe for CYP2B6 activity (Kharasch et al., 2008) and to
investigate potential CYP2B6 drug interactions in in vivo pharmaco-
kinetic studies (Hogeland et al., 2007). It has been shown that CYP2B6
polymorphisms influence thepharmacokinetics of bupropion (Kirchheiner
et al., 2003). However, reports of the effects of variant alleles on
bupropion’s pharmacokinetics and clinical outcomes are conflicting and
the relationship between its pharmacokinetics and CYP2B6 activity has
not been firmly established in vivo. In contrast,CYP2B6 polymorphisms
could influencemetabolism of efavirenz and consequently be associated
with differences in clinical outcomes (Gounden et al., 2010). Thus
efavirenz might be a useful CYP2B6 probe substrate in vivo. However,
evidence of important drug-drug interactions between efavirenz and
other CYP2B6 substrates is limited, and practical use of efavirenz as
a probe substrate is restricted by concerns regarding human immuno-
deficiency virus resistance in individuals for whom HIV status is not
known.
In this cohort-comparison study, we investigated the relationship
between bupropion metabolism and sex, ethnicity, and CYP2B6 genetic
polymorphism. Four cohorts of normal healthy adult volunteers were
studied: Caucasian-American men (CAM), Caucasian-American women
(CAW), Hispanic-American women (HAW), and African-American
women (AAW). The polymorphisms investigated were defined by single
nucleotide polymorphisms known to alter CYP2B6 function.
Materials and Methods
Study Design. All subjects in the four cohorts received a fixed open-label
dose of bupropion (BU) as a probe substrate for the determination of CYP2B6
activity. Activity was measured as the log10-transformed metabolic ratio of
hydroxybupropion (HB) to BU concentrations in blood drawn 6 hours
postdose. The single time point concentration ratio method was supported by an
analysis of pharmacokinetic data from a previous BU study with 12 healthy
volunteers (Hogeland et al., 2007) in which serial blood concentrations
suggested that at time points between 6 and 48 hours, log10(HB) and log10(HB/
BU) concentrations were correlated with log10[HB AUC(area under the
curve)o-‘] and log10[(HB AUCo-‘)/(BU AUCo-‘)], respectively. Upon analysis,
the 6-hour time point was chosen because of its high correlation (correlation
coefficient 0.91, R2 = 0.76) between the concentration ratio and AUC ratio
(unpublished data). Each of the four cohorts comprised 25 healthy adult
volunteers of ages 18–50 years. All subject groups studied lived in the same
area. Each subject had reported that their four grandparents shared a common
race/ethnicity. Eligibility did not depend on height, weight, or body mass index
(BMI). Screening for eligibility was based on self-reported ethnicity, medical
history, screening physical examination and interview, vital signs, and clinical
laboratory measurements [sodium, potassium, chloride, bicarbonate, the blood
urea nitrogen test, creatinine, glucose, calcium, magnesium, phosphorous, total
bilirubin, total protein, albumin, aspartate aminotransferase, alanine amino-
transferase, alkaline phosphatase, gamma-glutamyl transpeptidase, and lactate
dehydrogenase, coagulation panel (prothrombin time/ partial thromboplastin
time), and urinalysis]. Exclusion criteria included the following: ongoing
medical illness; allergy to BU; history of seizures or gastrointestinal/
hepatobiliary surgery; reported history of alcohol abuse, smoking, illicit drug
use; use of prescription medication within the past month or grapefruit juice and
over-the-counter medication during the last two weeks; use of oral contraceptives
or lactating or pregnant. Any laboratory value clinically significantly outside the
reference ranges previously established by the McLendon Laboratories of the
University of North Carolina Hospitals was also grounds for exclusion.
The study was conducted at the Verne S. Caviness General Clinical
Research Center at the University of North Carolina (UNC) at Chapel Hill from
July 1, 2006 to November 6, 2007. Subjects arrived after an overnight fast.
Women of child bearing potential had a urine pregnancy test prior to dosing
performed at McClendon UNC Hospital Laboratory. Each subject received
a fixed sustained-release oral dose of 150 mg bupropion (GlaxoSmithKline;
Lot# 6ZP2500), along with 240 ml of water. In this case subjects received
a fixed amount (150 mg) rather than the same dosage of BU. This necessitated
a weight-adjusted dose normalization of plasma concentrations before statistical
analysis, because subjects received different BU dosage calculated on a per
kilogram body weight basis. All subjects were instructed not to eat and drink
alcoholic or caffeine-containing beverages until the 6-hour blood sample was
drawn. However, drinking water was allowed.
The study protocol and subject-informed consent were approved by The
University of North Carolina Institutional Review Board and Research
Involving Human Subjects Committee of the Food and Drug Administration.
The study has been carried out in accordance with The Declaration of Helsinki.
Written consent was obtained from each participant.
Blood Sample Collection. For BU and HB quantification, blood was taken
prior to BU dosing and 6 hours postdose. A 7-ml sample of blood was drawn
from a forearm vein into sterile sodium EDTA tubes. Upon collection, tubes
were placed on ice for 30 minutes and plasma was separated by centrifugation
at 3000 rpm for 15 minutes at 24°C. Plasma was then aliquoted into cryovials
and stored at 280°C until analysis. For genotyping of CYP2B6, blood was
collected prior to BU administration.
CYP2B6 Genotyping. Genomic DNA was extracted from the peripheral
whole blood of each subject by use of a DNA extraction kit (Qiagen, Valencia,
CA). CYP2B6 SNPs at intron 3 branch point (15582C.T), exon 4 (516G.T;
Q172H, rs3745274), exon 5 (785A.G; K262R, rs22794343), exon 7 (983T.C,
I328T, rs2399499), and exon 9 (1459 C.T, R487C, rs3211371) were genotyped
by resequencing. Respective exons were amplified using intronic primers and
the polymerase chain reaction (PCR) conditions described earlier (Lambda et
al., 2003). Prior to sequencing, unincorporated nucleotides and primers were
removed by incubation with shrimp alkaline phosphatase (USB; Cleveland,
OH) and exonuclease I (USB) for 30 minutes at 37°C, followed by enzyme
inactivation at 80°C for 15 minutes. Sequencing was carried out with an ABI
Prism 3700 Automated Sequencer using the PCR primers or internal primers
(sequence available on request). Sequences were assembled using the Phred-
Phrap-Consed package (University of Washington; Seattle, WA; http://droog.
mbt.washington.edu/PolyPhred.html), which automatically detects the presence
of heterozygous single nucleotide substitutions by fluorescence-based sequenc-
ing of PCR products (Nickerson et al., 1997).
BU and HB Assays. BU and HB plasma concentrations were quantified
using an Agilent 1100 Series liquid chromatography-mass spectrometry
(Agilent Technologies, Santa Clara, CA) with positive electrospray ionization.
Blood plasma samples obtained from subjects 6 hours after bupropion
administration were thawed, and 10 ml of 4 mg/ml tripolidine (internal
standard) was added to 250 ml of the sample. Chromatographic separation was
carried out on a Phenomenex C8 (3.2  100 mm, 3.0 mm) column with
gradient elution (4% to 50% acetonitrile in 5 mM ammonium acetate, pH 4.6)
at a flow rate of 0.3 ml/min. All analytes were converted to free bases by
addition of 100 ml of 0.1 N potassium hydroxide. Liquid-liquid phase
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extraction was performed with 1.5 ml hexane:isoamyl alcohol (96:4). The
organic layer was collected, and 50 ml of 4 N hydrochloric acid was added to
each sample. The eluted solutions were taken to dryness in a Turbo Vap LV
evaporator (Zymark Corporation, Hopkinton, MA), then the residues were
reconstituted in 150 ml of the mobile phase and 25 ml of sample solution was
injected into Agilent 1100 Series liquid chromatography-massspectrometer.
Liquid chromatography-mass spectrometry analyses were carried out with the
use of positive electrospray ionization. Chromatographic separation was
performed on a Phenomenex C-8 (3.2  100 mm, 3.0 mm) column with the
use of gradient elution with a flow rate of 0.3 ml/min. Mobile phase A consisted
of 4% acetonitrile and 96% water containing 5 mM ammonium acetate at pH 4.6.
Mobile phase B consisted of 50% acetonitrile and 50% water containing 5 mM
ammonium acetate at pH 4.6. The lower limit of quantification was 1 ng/ml for
both analytes. Inter-and intraday coefficients of variation were #10%. The
analytical precision of each series was controlled by including two standard
solutions spiked with 20 and 100 ng/ml of bupropion and 50 and 200 ng/ml
hydroxibupropion, respectively. Buproprion was purchased from Sigma, (St.
Louis, MO) and hydroxybuproprion was purchased from Gentest, BD Bioscience
(Woburn, MA).
Data Analysis Strategy. Descriptive statistical methods were used to
compare the four cohorts in terms of age (years), height (cm), weight (kg), and
body mass index (kg/m2). At the time of the study, BU was only available in
a fixed, 150 mg sustained-release dosage form. Therefore, subjects could not
receive a dose of BU adjusted for differences in body weight. Without
normalizing BU plasma concentrations for differences in the actual dose per
kilogram body weight each subject received, BU plasma concentrations would
vary inversely to body weight and volume of distribution. Accordingly, prior
to analysis, all 6-hour BU and HB concentrations were adjusted to corre-
spond to a standard dose for a 70-kg weight individual. These dose-adjusted
(normalized) BU and HB concentrations were then transformed to log10 scale
because previous studies had suggested that these concentrations arise from
underlying population distributions that are approximately log-normal (Julious
and Debarnot, 2000; Edwards et al., 2001). The dose-adjusted and transformed
variables, log10 (BU) concentrations and log10 (HB) concentrations, are
hereafter referred to as logBU and logHB, respectively. Log10 (HB/BU) or
log10 metabolic ratio is hereafter referred to as logMR (metabolic ratio).
The primary aims of the study were achieved by model-based analysis of
mean logMR relative to logBU concentrations and subject characteristics. The
assumed linear statistical model for the logarithm of the metabolic ratio
represented mean logMR as a function of logBU concentrations and other
covariates representing cohort and genotype and other selected subject
characteristics. This analysis of covariance (ANCOVA) model for logMR is
linearly equivalent to an ANCOVA model for logHB in which the regression
equation includes the very same covariates: logBU concentrations, cohort,
genotype, and other characteristics. By virtue of this linear equivalence, all
results of the ANCOVA analysis are invariant regardless of whether the
dependent variable is logHB or logMR. We chose to focus on logMR as the
primary outcome variable for analysis. The analysis results presented would
not be altered by using logHB as the primary outcome variable.
To compare the three ethnic populations (AAW, caucasian,HAW)with respect
to prevalence of variant genotypes, ethnicity-specific genotype frequencies were
tabulated along with corresponding 95% confidence intervals. For each of five
CYP2B6 polymorphisms (in intron 3, exon 4, exon 5, exon 7, exon 9), a Fisher’s
exact test procedure of size a = 0.0125 was used to test the null hypothesis “no
differences among the three ethnic populations.”The size of the test,a = 0.0125 =
0.05/4 instead of 0.05/5 (i.e., a Bonferroni adjustment for multiple comparisons)
was used to account for the well described linkage disequilibrium between exon 4
and exon 5 and the almost perfect redundancy between these two alleles noted in
Table 3. If at least one of the five P values was smaller than a = 0.0125 then the
overarching null hypothesis (Ho) “no differences among the three ethnic
populations with respect to genotype prevalence rates for these five genotypes”
was to be rejected.
To characterize the relationship between logMR and ethnicity, sex, and
genotype, anANCOVAmodelwas fitted inwhich the dependent variablewas log
MR, and the independent variables included the covariate logBU concentrations
centered at its mean (1.83 ng/ml), terms representing membership in the four
cohorts, and terms representing genotype with respect to intron 3, exon 5, and
exon 9. Due to differences in CYP2B6 haplotypes in different ethnic groups, the
effects of CYP2B6 genetic variation may vary in these populations. Therefore we
assumed that the effects of any variant genotype may not be the same from one
ethnic group to another. Accordingly, the model also included interaction terms
representing differential effects of intron 3, exon 5, and exon 9 across cohorts. It
should be noted that the data did not support additional inclusion of exon 4, exon
7, and exon 9 in the model: the values for exon 4 were highly redundant of those
for exon 5 due to linkage disequilibrium (note: these two polymorphisms are
commonly designated as theCYP2B6*6 allele), and the values for exon 7 and exon
9 varied little across subjects.
Fitting the primary ANCOVA model to the data provided statistical
estimates of the parameters (i.e., regression coefficients). These statistical
estimates were used to compute tests of hypotheses and to compute estimates of
mean log MR at given levels of cohort, genotype (intron 3, exon 5, exon 9), and
logBU. Mean differences defining direct effects of cohort membership, and
mean differences defining direct effects of genotype, as well as differences
between mean differences that define genotype-by-cohort interaction effects
also were estimated.
A second primary test was performed regarding genotype: to establish that
intron 3, exon 5, and exon 9 have predictive value even when cohort
membership is taken into account, an F-test procedure of size a = 0.05 was
used to test the null hypothesis (Ho) “intron 3, exon 5, and exon 9 have no
predictive value.” If, as expected, Ho was rejected, then further tests of
component subhypotheses were to be performed; e.g., Ho (1) “intron 3 has no
predictive value,” etc. Similarly, a secondary hypothesis test was performed,
designed to detect the existence of any association between logMR and cohort
membership that remained after having accounted for genotype. If this overall
Ho was rejected, then further tests of component subhypotheses were to be
performed (HAW versus AAW, etc.). This hierarchical hypothesis testing
strategy was designed to control the overall rates of type I error while
optimizing statistical power (Muller and Stewart 2006).
In support of the primary analyses, we performed conventional diagnostic
computations (e.g., analysis of residuals) with graphical and tabular summaries
of the results. We also performed a number of auxiliary analyses to evaluate the
robustness of the primary results to perturbations of the assumptions and
methods. The auxiliary analyses included fitting the primary model with the
following: exon4 replacing exon 5 in the regression equation, omitting the
genotype-by-subpopulation interactions, and several other analyses.
Several secondary and exploratory analyses also were performed as part of
the comprehensive examination of the data. As an aid to interpretation of
primary results, the genotype variables were excluded from the primary model
and a secondary hypothesis (H0), “the sex/ethnicity subpopulation differences
are zero,” was tested to demonstrate the existence of sex/ethnicity differences
when genotype was not taken into account. The predictive value of age and
BMI or weight was explored by modifying the primary model to include
additional covariates in the model. Additional covariates considered were
centered at their sample means [(age-27), (BMI-26), (weight-72), (height-167),
(timing of blood draw-6)], and terms representing them were included in the
regression equation. Finally, as an aid to the interpretation of the primary
results, an auxiliary analysis was performed to examine the relationship
between logBU concentrations and ethnicity, sex, and genotype. For this
ANCOVA model the dependent variable was logBU concentrations and the
independent variables were the same as in the primary analyses.
All statistical computations were performed using SAS System software
(version 9.2; SAS Institute Inc., Cary, NC). The fitting of the linear regression
models reported relied on algorithms provided by mixed linear model
procedure and an F-test procedure of size a = 0.05 was used to test hypotheses.
Confidence intervals for variance parameter estimators were obtained via mixed
linear models procedure. Influence diagnostics (e.g., Cook’s Distance, the
PRESS statistic, etc.) were computed using linear regression model procedure.
In sensitivity analyses, auxiliary robust regression methods were implemented
using nonlinear model procedure.
Results
Descriptive Tabulations. The four cohorts were similar in age. The
men were taller, on average, than the women. Average weight was
greatest for the AAW and CAM cohorts. Weights across the four
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cohorts ranged from 44 to 130 kg. The CAW cohort had the lowest
average BMI, whereas the AAW cohort had the highest average BMI
(Table 1).
Blood samples used were withdrawn 6 hours postdose. At 6-hour
time point mean sampling times and standard deviations were: 6.01 6
0.41 hours; 6.03 6 0.94 hours; 6.03 6 0.64 hours, and 6.03 6 0.12
hours for CAM, CAW, AAW, and HAW, respectively. Geometric
means with corresponding 95% confidence intervals are shown in
Table 2 for dose-adjustedBU andHBconcentrations at 6 hours postdose
and for the calculated MR. Whereas the mean BU concentration for
Hispanic women was lower compared with the other three cohorts,
mean HB concentrations were similar that resulted in an approximately
50% higher MR for Hispanic women.
Association between CYP2B6 Genotype Frequency and Race/
Ethnicity. Table 3 depicts the distribution of the genotypes of the
major functional CYP2B6 polymorphisms for each of the four cohorts.
Associations between ethnicity and frequency for any of the five
studied genotypes were not detected. Although there appeared to be
differences in variant allelic frequency among ethnic groups for intron
3, we were unable to conclude these differences are real based on
a prespecified adjustment for multiple genotype comparisons.
Dependence of CYP2B6 Activity on Race/Ethnicity, Sex, and
CYP2B6 Polymorphisms. The primary analysis used an ANCOVA
model for logMR to evaluate the predictive value of logBU
concentrations, sex, ethnicity, genotypes (intron 3, exon 5, exon 9)
and genotype-by-sex/ethnicity interactions. Because exon 4 and exon
5 polymorphisms are in almost complete linkage disequilibrium, only
exon 5 was included in the first analysis to save degrees of freedom
and preserve power. Within the range of log-BU concentrations
experienced by the subjects, the fitted model indicated that logHB
concentration increases by 0.13 units for every one-unit increase in log
BU concentration (P , 0.0001). Association of logMR with sex and
ethnicity was not detected (P = 0.7325). In contrast, the null
hypothesis that the five genotypes have no predictive value was
rejected (P = 0.0033). Occurrence of variant intron 3 (P = 0.0013) or
exon 5 (P = 0.0017) was associated with lower activity compared with
subjects with wild-type intron 3 and exon 5. Association with exon 9
was not detected (P = 0.7415). The null hypothesis that the
magnitudes of the genotype effects are the same for all three ethnic
populations was not rejected; i.e., the genotype-by-ethnicity in-
teraction terms in the model were not statistically significant (P =
0.3275).
Table 4 illustrate estimates of mean logMR for the four sex/
ethnicity cohorts for four genotype profiles: wild type for all three
CYP2B6 genotypes, variant only in intron 3, variant only in exon 5, or
variant only in exon 9. HB/BU metabolic ratio was much greater in
Hispanic women, as 16 out of 26 HAWs had a variant intron 3, and
this variant is associated with lower metabolism (P , 0.0148).
When exon 4 was included in the regression equation in place of
exon 5 the results were identical using either exon 5 or exon 4, which
is expected because the two polymorphisms are in almost complete
linkage disequilibrium. Two subjects had extremely low logMR
values. Neither a deletion of these two subjects nor the use of robust
regression methods provided a better fit to the data or led to a different
interpretation of the results. Finally, inclusion of age and BMI in the
primary model produced results that were fully consistent with those
obtained via the primary model.
Relationship between Bupropion Concentrations and Subject
Characteristics. A supportive analysis with logBU concentrations as
the dependent variable was performed. The null hypothesis (H0) that
cohort effects and genotype-by-cohort interactions are all zero was
rejected (P = 0.0243). Hierarchical testing of component subhypo-
theses detected ethnicity differences, with Hispanic Americans having
a lower mean logBU concentration than African Americans and
Caucasian Americans. No differences between African Americans and
Caucasian Americans were detected. An additional test designed to
detect the existence of genotype differences not accounted for by sex/
ethnicity cohort membership also was not statistically significant.
Discussion
BU is an antidepressant and in humans is metabolized to three
major metabolites: erythrohydrobupropion, threohydrobupropion, and
HB. The hydroxylation of BU to HB has been validated in vitro
(Faucette et al., 2000) as a specific measure of CYP2B6 activity in
liver microsomes. However, as opposed to in vitro incubations with
microsomal preparations, clinical investigations are potentially compli-
cated by competing metabolic pathways, as well as by renal and/or
biliary elimination (Welch et al., 1987). Such alternative pathways of
elimination may confound the relationship between CYP2B6 poly-
morphisms and CYP2B6 activity in the liver as measured by the in vivo
clearance of BU. The extent to which carbonyl reduction of BU to
erythrohydrobupropion and threohydrobupropion competes with CYP2B6-
mediated hydroxylation of BU in the liver is not known.
The purpose of this study was to identify important covariates that
are associated with interindividual variation in CYP2B6 activity using
the metabolism ratio of BU to HB as a surrogate measure. Knowledge
of such covariates would further inform investigations intended to
validate BU as a useful clinical probe. We hypothesized that specified
CYP2B6 polymorphisms would account for any sex or ethnic dif-
erences in BU that might be observed. In this study, there was no
association of sex or ethnicity with CYP2B6 activity as measured by
the HB/BU MR. However, an association was seen between CYP2B6
activity and polymorphisms in exon 5 and intron 3. In addition, the
results also suggest that the effect of the variant alleles on CYP2B6
activity was similar for both sexes and all ethnic groups examined.
The current study is the first to use bupropion metabolic ratio at a
single time point to develop a model for evaluating CYP2B6 activity.
A traditional dense concentration-time method of pharmacokinetic
data analysis for this study would be preferable but would require
upwards of 10 to 12 concentration-time samples per patient and would
be clinically prohibitive. Therefore, a single 6-hour time point was
selected for calculation of MR, guided in part by data from a previous
study conducted by our research group. Using this approach, we found
that the exon 5 allelic variant of CYP2B6, as well as the intron 3
variant, was independently associated with lower metabolic ratio
compared with subjects with wild-type exon 5. The association of the
TABLE 1
Descriptive tabulations for age and body size (N = 100)
Only descriptive statistics were performed on these data. Values are expressed as mean6 S.D.
The potential influence of these demographic variables in the analysis was addressed by









Age (years) 25.7 6 7.5 27.6 6 7.4 27.6 6 7.6 26.2 6 8.2
Range 18–46 18–41 18–49 19–44
Height (cm) 178.7 6 11.0 164.5 6 5.8 164.4 6 4.9 161.4 6 5.6
Range 159.5–211.0 152.0–176.4 156.0–173.0 149.3–172.1
Weight (kg) 80.3 6 8.3 60.6 6 9.1 83.1 6 22.4 63.2 6 8.9
Range 65.0–99.3 44.4–80.5 52.8–129.7 44.5–81.6
BMI (kg/cm2) 25.4 6 4.0 22.3 6 2.7 30.9 6 8.5 24.3 6 3.4
Range 17.5–39.0 18.1–29.9 20.1–51.4 19.1–30.9
AAW, African-American women; BMI, body mass index; CAM, Caucasian-American men;
CAW, Caucasian-American women; HAW, Hispanic-American women.
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exon 5 variant with lower metabolic ratio and our approach are
supported by the recent report by Chung et al. (2011) where a
metabolic ratio, calculated as the ratio of HB AUC0-36 hours to BU
AUC0-36 hours, was lower in CYP2B6*6 (this nomenclature denotes the
linked exon 4 and exon 5 variants) carriers than in CYP2B6*6
noncarriers among 35 healthy volunteers administered the same BU
product at the same dose as used in our study. However, the small
sample size per group, the absence of male group for each ethnicity,
the reliance on the limited pharmacokinetic data based on 6-hour
sampling time, the influence of alternative routes of elimination, and
the extent of secondary metabolism of HB that has been described
(Chung et al., 2011) should be considered as factors that potentially
limit the findings of this study.
Women’s livers have been reported to have higher amounts
of CYP2B6 mRNA, protein, and activity than men’s livers, and
a CYP2B6 genotype-phenotype association was observed in livers
obtained from women (Lamba et al., 2003). However, these previous
investigations used human liver microsomes and the biotransformation
of S-mephenytoin to nirvanol as a measure of CYP2B6 activity. We
found no sex differences in bupropion metabolic ratio in our log-scale
model-based analysis, although our findings are limited to Caucasian
men and women. Our data suggest that there may not be clinically
significant sex differences in human CYP2B6 activity or our methods
were not sensitive enough to detect a small difference. Ethnic dif-
ferences in CYP2B6 activity have also been observed when a human
liver microsome assay was used (Lamba et al., 2003; Parkinson et al.,
2004). Samples obtained from Hispanic women had 3.6- and 5.0-fold
higher CYP2B6 activity compared with liver microsomes taken
from Caucasian women and African-American women, respectively
(Lamba et al., 2003). In this in vivo study, ethnic differences were
observed in bupropion concentrations, with Hispanic women hav-
ing lower concentrations even after dose adjustment compared with
Caucasian and African-American women. However, there were no
statistically significant differences in the bupropion metabolic ra-
tio using our primary model. As mentioned above, the reduction of
bupropion by hepatic carbonyl reductase represents a competing
pathway of metabolism and may account for our observations in
Hispanic women. For example, higher rates of carbonyl reduction in
Hispanic women might result in lower plasma bupropion concen-
trations without observing an effect on CYP2B6-mediated hydroxyl-
ation if Michaelis constants (Km) for bupropion reduction are much
greater than the Km for BU hydroxylation. Such effects would increase
variability in the BU MR, perhaps confounding our ability to detect
differences. Similarly, differences in the disposition and retention of
BU and HB in various tissue compartments (e.g., related to their
partitioning in low BMI or high BMI subjects), reflecting differences
in their physiochemical properties, and in the polymorphic drug
transport processes involved in their uptake and elimination will also
increase variability in the MR. In addition, slow release of BU in
the gastrointestinal tract, associated with the sustained release BU
TABLE 2
Bupropion and hydroxybupropion 6-hour concentrations (ng/ml) and metabolic ratio across sex/ethnicity cohorts (N = 100)
Values are expressed as geometric means (695% confidence intervals). As statistical analysis is more appropriately performed using analysis of covariance
(ANCOVA) on log-transformed data, these tabulations are provided only for descriptive purposes. Each group had 25 patients.
Unadjusted Dose-Adjusteda
BU HB BU HB HB/BU
CAM 66.67 (57.99–76.65) 260.95 (206.40–329.92) 76.10 (66.19–87.50) 297.88 (235.44–376.89) 3.92 (3.08, 5.00)
CAW 83.62 (73.14–95.60) 354.77 (317.59–396.30) 71.56 (63.82–80.25) 303.61 (271.80–339.14) 4.24 (3.62, 4.97)
AAW 66.13 (53.67–81.49) 258.55 (191.14–349.73) 75.92 (61.43–93.84) 296.81 (224.46–392.49) 3.97 (2.80, 5.64)
HAW 55.60 (43.89–70.44) 330.90 (282.86–387.10) 49.74 (38.48–64.31) 296.05 (256.49–341.71) 6.01 (4.60, 7.85)
AAW, African-American women; BU, bupropion; CAM, Caucasian-American men; CAW, Caucasian-American women; HAW, Hispanic-American women; HB,
hydroxybupropion.
a Prior to computation of the geometric mean, plasma concentrations were adjusted to correspond to a standard dose for a 70-kg weight individual.
TABLE 3
Genotype frequencies by sex/ethnicity cohorts














Intron 3 Variant 11 13 6 16 46 *0.0148
Wild type 14 12 19 9 54
VAF 22% 34% 12% 44% 28%
Exon 4 Variant 10 12 16 12 50 0.4029
Wild type 15 13 9 13 50
VAF 24% 28% 34% 28% 28.5%
Exon 5 Variant 11 13 16 12 52 0.1163
Wild type 14 12 9 13 48
VAF 26% 30% 36% 30% 30.5%
Exon 7 Variant 0 0 1 0 1 0.5000
Wild type 25 25 24 25 99
VAF 0% 0% 2% 0% 0.05%
Exon 9 Variant 5 5 2 3 15 0.4380
Wild type 20 20 23 22 85
VAF 10% 10% 4% 6% 7.5%
AAW, African-American women; CAM, Caucasian-American men; CAW, Caucasian-American women; HAW, Hispanic-American women; VAF, variant allelic
frequency.
a Fisher’s exact test of the null hypothesis of no association between genotype and ethnic group (AAW, HAW, caucasian). *P value less than a = 0.0125 was
considered statistically significant.
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formulation used in our study, would have a more rate-limiting effect
on BU metabolism in individuals with high CYP2B6 activity
compared with those with low activity. Similarly, the hydroxylation
of BU is also catalyzed to a lesser extent by other highly polymorphic
P450s that vary in concentration in human liver, and these would have
a greater contribution in individuals with low CYP2B6 activity. These
other factors would tend to reduce the range in the MR observed in our
study.
Association between the CYP2B6 genotypes and sex/ethnicity
cohorts was not detected in this study. It had been previously
conjectured that a possible reason for ethnic differences in CYP2B6
activity could be differences in genotypic frequency. It was thought
that differences in allelic frequency could, in part, explain ethnic group
differences observed in CYP2B6 liver microsomal activity. In previous
studies, intron 3 was found to be associated with lower CYP2B6
expression in women, exon 9 was associated with the lowest level of
CYP2B6 activity in women’s livers, and exon 4 516G.T was shown to
disrupt an exonic splice enhancer (Lamba et al., 2003; Thorn et al.,
2010). The exon 5 785A.G is frequently present in combination with
exon 4 516G.T in the CYP2B6*6 haplotype. This haplotype is
associated with lower CYP2B6 protein expression and BU hydroxyl-
ation in liver microsomes (Thorn et al., 2010). In our study, we detected
an association between these functional CYP2B6 genotypes and
CYP2B6 activity. Subjects having at least one variant allele tended to
have a lower BU metabolic ratio than those carrying wild-type alleles;
however, our results suggest the association of these variant alleles with
lower metabolism is similar across all ethnic groups examined.
Variability in CYP2B6 activity and expression may depend on the
combination of polymorphisms present in an individual. Also different
genotypic combinations (haplotypes) may have different effects in
different ethnic groups depending on other factors such as the
transcription factor constitutive androstane receptor, which reflects
environmental effects such as other drugs. However, because no
interactions were detected between genotype and ethnicity, we have
no direct evidence to conclude that there are differences in genotypic
effects across different ethnic groups.
By using HB/BU metabolic ratio as a measure of CYP2B6 activity,
we were able to confirm the influence of genetic variants that may be
responsible for altered CYP2B6 function. Alterations in CYP2B6
activity may lead to differences in systemic exposure of drugs
metabolized by CYP2B6 and therefore result in variation in therapeutic
and toxic responses to these drugs in certain populations. Our results
from this preliminary study suggest that only CYP2B6 genotype has an
association with CYP2B6 activity. These results are encouraging and
may allow for bupropion to be used as a probe substrate across sex and
ethnicities as a measure of CYP2B6 activity. However, a formal
prospective study that includes both men and women among all study
groups and using a more optimized blood sampling time is needed to
develop a robust predictive model for future clinical use.
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